A new ICR study has provided insights into an important biological mechanism that supports survival of aggressive, hard-to-treat cancers. – The Institute of Cancer Research
Recently, The Institute of Cancer Research shared on LinkedIn:
“NEWS: A new ICR study has provided insights into an important biological mechanism that supports survival of aggressive, hard-to-treat Cancers.
In the new study, led by Professor Wojciech Niedzwiedz, leader of the Genome Instability and Cancer group and published in Nature Communications, researchers identify a new cellular role of a protein called EXD2 nuclease and, importantly, its role in the so-called ALT pathway.
The study, which was funded by the ICR itself and Cancer Research UK (CRUK), also provides potential new targets, against which cancer drugs could be developed for patients who currently have limited therapeutic options.”
For details click here.
Source: The Institute of Cancer Research/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023